Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
62 hedge funds and large institutions have $755M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 18 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less funds holding
Funds holding: 68 → 62 (-6)
11% less capital invested
Capital invested by funds: $848M → $755M (-$92.5M)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.01M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$7.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$18.4M |
| 2 |
VMI
VHCP Management III
New York
|
-$9.46M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.21M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.08M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$2.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LI
76
Leap Investments
Chicago,
Illinois
| – | -$171K | -1,220 | Closed |
|
|
LA
77
Legacy Advisors
Plymouth Meeting,
Pennsylvania
| – | -$41K | -295 | Closed |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| – | -$21K | -149 | Closed |
|
79
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$5K | -40 | Closed |
|
|
PHK
80
Point72 Hong Kong
Hong Kong
| – | +$419 | +3 | New |
|
ORTX Hedge Fund Activity: Q3 2019 in Review
62 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2019, worth a combined $755M — down 11% from $848M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ORTX and 13 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 26 added.
The largest buyer was Adage Capital Partners, adding an estimated $22.7M. The largest seller was Vivo Capital, exiting entirely with an estimated $18.4M sold.
- 62 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2019, down from 68 in Q2 2019.
- Funds reported $755M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2019, down 11% quarter-over-quarter.
- 13 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2019 and 18 closed out, a net change of -5 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2019 was Adage Capital Partners, an estimated $22.7M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2019 was Vivo Capital, an estimated $18.4M sold.
Based on aggregated 13F filings for Q3 2019.